A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE2
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Cabozantinib With Topotecan-Cyclophosphamide
- Status
- COMPLETED
- Phase
- PHASE1
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients
- Status
- TERMINATED
- Phase
- PHASE3
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
- Status
- UNKNOWN
- Phase
- PHASE1
CAR-T Cells for HIV Infection
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
NeoTIL in Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
- Status
- RECRUITING
- Phase
- PHASE3
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
- Status
- RECRUITING
- Phase
- PHASE1
FT819 in Subjects With B-cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
CAR-T Cells in Treating Patients With Relapsed or Refractory NHL
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1